Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Pfizer Inc. Add to portfolio

NYA:PFE, Mar 26, 11:22 UTC

Latest NYA:PFE News

Filter your feed

Apply Filter

Yesterday


Social Chatter

Pfizer Inc. (NYA:PFE) social chatter is higher than usual

PFE
Beto's new campaign manager, Jennifer O’Malley Dillon, comes from Precision Strategies, a corporate strategy firm that has repped GE, Bank of America, Humana, Pfizer and Facebook, among others.

Thursday, March 21


News

Global Hodgkin's Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com

PFE BMY +1 more PFE BMY MRK

Global Hodgkin's Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com. The hodgkin's lymphoma drugs market will register a CAGR of close to 16% by 2023. In addition, the introduction of target molecular hallmarks of this disease, including the aberrant phenotype of cancer cells, deregulated cancer pathways, and immune escape mechanisms. The treatment of Hodgkin's lymphoma has generally been successful and well-tolerated by patients. However, there are challenges associated with the treatment of patients that have Hodgkin's lymphoma with conjoint conditions, such as cardiac diseases, HIV infection, and pregnancy.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, March 20


News

Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

PFE

Data from a planned interim analysis showed that the study will not achieve superiority in the pre-specified primary endpoint of progression-free survival (PFS). First, the degree of benefit observed with avelumab in frontline ovarian cancer in the JAVELIN Ovarian 100 study did not support continuation of the JAVELIN Ovarian PARP 100 study, the companies said or for that matter evaluating an immunotherapy in ovarian cancer itself. Though Bavencio is a relatively new drug in Pfizer’s oncology portfolio and is currently approved for two relatively smaller indications, it might emerge as a key long-term growth driver for Pfizer on future label expansion approvals. Pfizer is also conducting avelumab double/triple combination studies for chemotherapy and targeted therapies and has several avelumab combination therapies with immuno-oncology agents under development. However, several studies on Bavencio have failed in the past.

Read Full Details

Topics:
  • Business
  • Health
News

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

PFE

were falling slightly in premarket trading after the giatn drugmaker announced it has agreed to pay up to $636 million for the rights to a portfolio of gene therapies under development at French company Vivet Therapeutics. Pfizer acquired a 15% equity interest in Vivet up front for $51 million and secured an exclusive option to acquire all of the private company's outstanding shares. The two companies will collaborate on Vivet's propriety treatment for the chronic, life-threatening liver disorder Wilson disease.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Pfizer buys stake in French gene therapy firm Vivet

PFE

(Reuters) - Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease. Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company. Pfizer already has collaboration agreements with gene therapy companies including Spark Therapeutics and Sangamo Therapeutics to target conditions like hemophilia and certain neurodegenerative disorders. In a joint statement on Wednesday, Vivet and Pfizer said Pfizer can exercise its option to acquire all of Vivet following its delivery of certain data from an early-stage clinical trial for its VTX-801, an experimental treatment for Wilson disease.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

PFE

The company said the drug will be available in late June following scheduling by the U.S. Drug Enforcement Administration, which is expected to occur within 90 days. Pfizer Inc. (NYSE: PFE) said it acquired a 15-percent equity interest in privately-held gene therapy company Vivet, and secured an exclusive option to acquire all outstanding shares of Vivet, Pfizer also said it will collaborate with Vivet on the development of VTX-801, Vivet's proprietary treatment for Wilson disease, a life-threatening liver disorder. TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) announced the submission of IND to the FDA to initiate Phase 1 trial of enteric-coated capsules of Foralumab in healthy volunteers. MOTIF BIO PLC/S ADR (NASDAQ: MTFB) said the FDA has granted it, its request for a Type A meeting to discuss the points raised in the complete response letter for the NDA for iclaprim for the treatment of acute bacterial skin and skin structure infections.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million

PFE

Pfizer Inc. said Wednesday it has paid 45 million euro, or the equivalent of $51 million to acquire a 15% equity stake in privately held gene therapy company Vivet Therapeutics, and has acquired an option to buy the rest of Vivet shares for EUR560 million ($635.8 million). Pfizer and Vivet will collaborate on developing VTX-801, Vivet's treatment for Wilson disease, a life-threatening liver disorder of impaired copper transport. Under terms of the deal, Pfizer can exercise its option to buy 100% of Vivet after the company's delivery of certain data from the phase 1/2 trial for VTX-801. Monika Vnuk, vice president of worldwide business development at Pfizer, will join Vivet's board of directors.

Read Full Details

Topics:
  • Business
  • Financial
News

Pfizer buys stake in French gene therapy firm Vivet

PFE

(Reuters) - Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease. Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company. Pfizer already has collaboration agreements with gene therapy companies including Spark Therapeutics and Sangamo Therapeutics to target conditions like hemophilia and certain neurodegenerative disorders. In a joint statement on Wednesday, Vivet and Pfizer said Pfizer can exercise its option to acquire all of Vivet following its delivery of certain data from an early-stage clinical trial for its VTX-801, an experimental treatment for Wilson disease.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Technology

Tuesday, March 19


News

Pfizer (PFE) Gains As Market Dips: What You Should Know

PFE

Pfizer (PFE) Gains As Market Dips: What You Should Know. In the latest trading session, Pfizer (PFE) closed at $42.32, marking a +1.22% move from the previous day. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.86 per share and revenue of $52.90 billion. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Read Full Details

Topics:
  • Business
  • Financial
News

Analysts Reduce Pfizer’s Target Price in March

PFE

How Major Pharmaceutical Stocks Are Positioned This MonthAnalysts’ recommendations and target price Wall Street analysts expect a potential upside of 5.57% for Pfizer (PFE) based on the company’s closing price on March 18. In 2019, analysts have.

Read Full Details

Topics:
  • Business
  • Financial